The clothing company Polarn O. Pyret AB is acquired by Procuritas Capital Investors IV from RNB Retail and Brands AB (publ) at a preliminary purchase price of SEK 330 million on a cash and debt-free basis.

Polarn O. Pyret is a Swedish brand for baby and childrenswear that started in 1976 with the goal of making clothes that let kids be kids. Polarn O. Pyret is a leading brand for high-quality kids wear in the Nordics, and their products are sold in several markets around the world.

The transaction is subject to approval by seller’s bondholders and the Swedish Competition Authority.

Vinge’s team consisted of Jonas Johansson together with, among others, Stina Bengtsson and Mikaela Falkner (M&A), Karolina Cohrs (Real estate), Linn Adelwald and Ludvig Wettergren (Banking and Finance), Sara Strandberg and Emil Lindwall (Employment), Christoffer Nordin (Commercial Agreements), Sofia Bergenstråhle (IP), Agnes Perbo (IT), Tove Lövgren Frisk (Compliance), Johan Wahlbom (Competition law) and VDR-specialist Viktoria Owetz Leyva.

 

Related

Vinge advises Right Side Group, a portfolio company of Alder, in connection with the acquisition of Brandkonsultbyrån i Sverige

Brandkonsultbyrån in Sweden is a technical consultant specialising in structural fire protection, evacuation safety and risk management. The acquisition strengthens the group’s position as a leading player in fire, risk and safety in the Nordic region.
April 17, 2026

Vinge advises Vidia Climate Fund I in connection with the acquisition and acquisition financing of ABEKA El & Kraftanläggningar AB

Vinge has acted as legal adviser to Vidia Climate Fund I in connection with the acquisition and acquisition financing of ABEKA El & Kraftanläggningar AB from Bravida and certain minority shareholders. ABEKA El & Kraftanläggningar AB is a highly specialized electrical grid services and project management provider.
April 17, 2026

Vinge adviser in the sale of SAGA Diagnostics

Vinge acted as legal adviser relating to Swedish law in connection with the sale of SAGA Diagnostics to Roche’s subsidiary Foundation Medicine.
April 16, 2026